Safety Levels of Systemic IL-12 Induced by Cdna Expression As a Cancer Therapeutic.

The aim of this work is to utilize a gene expression procedure to safely express systemic IL-12 and evaluate its effects in mouse tumor models. Materials & methods: Secondary lymphoid organs and tumors from EL4 and B16 tumor-bearing mice were analyzed by supervised and unsupervised methods. Results: IL-12 cDNA induced systemic IL-12 protein levels lower than the tolerated dose in patients. Control of tumor growth was observed in subcutaneous B16 and EL4 tumors. Systemic IL-12 expression induced a higher frequency of both total tumor-infiltrated CD45(+) cells and proliferative IFN-gamma(+)CD8(+) T cells along with a lower frequency of CD4(+)FOXP3(+) and CD11b(+)Gr-1(+) cells. Conclusion: This approach characterizes the systemic effects of IL-12, helping to improve treatment of metastases or solid tumors. Lay abstract: IL-12 has emerged as a potent cytokine in mediating antitumor activity in preclinical models of cancer. However, this antitumor response has not yet been translated into the clinic because of toxic side effects. The aim of our work is to analyze the effects of IL-12 in mouse tumor models. We demonstrate that one injection of IL-12 cDNA can induce systemic IL-12 levels in serum even lower than the tolerated dose in patients. At this dose, an efficient control of tumor growth can be observed. We found a higher frequency of both total tumor-infiltrated leukocytes and IFN-gamma-producing CD8(+) T cells along with a lower frequency of regulatory CD4(+)FOXP3(+) and CD11b(+) Gr1(+) cells. Our work demonstrates that IL-12 cDNA can safely be used to treat cancer.